Stalevo (levodopa, carbidopa, and entacapone combination therapy) may be more effective but seems to be associated with more side effects than other medications to treat early Parkinson’s disease, researchers report. The study, “Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis,” was…
Fatigue may compromise and predict Parkinson’s patients’ mobility and their ability to walk over long distances, according to a recent study. The results of the study, “Can fatigue predict walking capacity of patients with Parkinson’s disease?” were published in Arquivos de Neuro-Psiquiatria. Lack of energy, or…
Two distinct proteins previously known to play key roles in the development of tremor associated with neurodegenerative diseases now have been found to interact directly, a discovery that might lead to new therapies for tremor-related movement disorders, including Parkinson’s disease. The study with that finding, “LINGO1 is a…
An investigational therapy known as NLX-112 (befiradol) may hold promise to treat levodopa-induced dyskinesia, a complication of long-term levodopa therapy that affects people with Parkinson’s disease, a study found. The study, “The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets,” was…
Blood levels of progranulin — a protein whose deficiency has been linked to neurodegeneration — may reflect Parkinson’s severity and progression, and serve as a disease biomarker, a recent study suggested. The research, “Reduced plasma progranulin levels are associated with the severity of Parkinson’s disease,” was published in…
People with Parkinson’s disease may have higher levels of selenium — a mineral with antioxidant properties — in their cerebrospinal fluid, the liquid that surrounds the brain and spinal cord, a study suggests. The research, “Selenium level does not differ in blood but…
Likely cognitive decline, dementia risk, and the severity of motor symptoms in Parkinson’s disease might be tracked by measuring the amount of iron content in the brain, a study reports. These finding were described in the study “Brain iron deposition is linked with cognitive severity in Parkinson’s disease,”…
Scientists have developed a new cellular model that can help reconstruct the entire process of Lewy body formation — a key event that underlies neurodegeneration in Parkinson’s disease — and that could potentially be used to evaluate the effect of therapeutics on the toxic protein buildup observed during this…
Scientists have uncovered a new therapeutic molecule, called BT13, that can get to the brain to boost dopamine levels — the brain chemical that’s in short supply in Parkinson’s disease — and could potentially protect against neurodegeneration. While the research is in the early stages, and the molecule…
Memory-related mild cognitive impairment in Parkinson’s disease may be associated with a more severe buildup of alpha-synuclein protein in the brain — such as that observed in more advanced stages of the disease, a study finds. The results of the study, “Neuropathological Findings in Parkinson’s Disease With…
Get regular updates to your inbox.